

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 27, 2025 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted.

Adoption of the income statement and the balance sheet; allocation of result

The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with submitted accounting documents. The Annual General Meeting further resolved to allocate the company's result in accordance with the board's proposal, i.e. that the amount at the disposal of the general meeting shall be carried forward in its entirety. The resolution entails that no dividend is paid for the financial year 2024.

Discharge from liability

The Annual General Meeting resolved to discharge the board members and the managing director from liability for the financial year 2024.

Election of board members and resolution on board remuneration

The ordinary board members Robert Burns, Gillian M. Cannon, Jonathan Knowles, Jakob Lindberg, Anders Martin-Löf and Mathias Uhlén were re-elected, and Rachel Humphrey and Filippa Stenberg were elected as board members, all for a term of office extending until the end of the next Annual General Meeting. Robert Burns was re-elected as chairman of the board.

It was resolved that the Board's remuneration for the time until the next Annual General Meeting shall amount to SEK 500,000 to the chairperson, SEK 350,000 to the vice chairperson (if the board appoints one) and SEK 250,000 to each of the other directors. In addition, it was resolved that a fee of SEK 100,000 shall be paid to the chairperson of the audit committee and a fee of SEK 25,000 to each of the members of the audit committee. It was further decided to give some additional compensation to directors residing outside of the Nordic countries in connection with physical board meetings in Sweden. No remuneration will be paid to Filippa Stenberg.

Auditor and resolution on remuneration to the auditor

The Annual General Meeting resolved to appoint the registered auditing firm Ernst & Young AB to be the auditor of the company for the period until the end of the next annual general meeting. Fees to the auditor shall be paid against approved invoice.

Authorization for issues of shares, convertibles and warrants

It was resolved to authorize the Board of Directors to, on one or several occasions during the period up to the next annual general meeting, increase the company's share capital through issues of new shares, convertible instruments and/or warrants, with or without deviating from the shareholder's preferential rights, and with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions.

About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody[®] molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Contacts

Affibody

David Bejker, CEO, +46 706 454 948

Peter Zerhouni, CFO and CBO, +46 706 420 044

Attachments

[Report from Annual General Meeting in Affibody Medical AB \(publ\)](#)